US Supply Of OTC COVID-19 Tests Gets Boost Through $231.8M Contract For Australian Firm
Biden administration seems to be betting Elluve's OTC at-home antigen diagnostic test will be a game changer in helping stop the spread of the coronavirus.
You may also be interested in...
Developer Of First US OTC COVID-19 Antigen Test Plans 'Digital Diagnostics For Multitude Of Infectious Diseases'
The developer of the OTC at-home antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the US government to manufacture in the US. So what’s next for Ellume? In this Q&A, the Australian company’s CEO, Sean Parson, explains.
“We see this is a as a significant opportunity, and quite frankly, a trend that's been happening overseas and is kind of now happening here in the US,” says Abbott Labs CEO Robert Ford.
Abbott’s’s distribution of its BinaxNOW COVID-19 Ag Self Test to US retailers increases to three the number of OTC tests for the virus that CVS offers, along with Ellume’s and Labcorp’s test kits also available under EUAs granted by FDA.